U.K. preparing for value-based drug-pricing system

03/24/2013 | Reuters

Beginning in 2014, Britain's National Institute for Health and Clinical Excellence will approve and price drugs based on broader measures, including the benefits to society. Firms with innovative, badly needed or highly effective medications, for example, could command higher prices. The new value-based initiative will replace the current system that caps the maximum return on investments that drug companies can earn.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA